Levulan® Kerastick® (aminolevulinic acid HCl) for Topical Solution, 20% (Levulan Kerastick) plus blue light illumination using the BLU-U® Blue Light Photodynamic Therapy Illuminator (Levulan PDT) is indicated for the treatment of minimally to moderately thick actinic keratosis of the face or scalp. Actinic keratoses (AKs) are rough-textured, dry, scaly patches on the skin that can lead to skin cancer. It is important to treat AKs because there is no way to tell when or which lesions will progress to squamous cell carcinoma (SCC), the second most common form of skin cancer. So, now’s the time to manage your damage!
Levulan PDT, a 2-part treatment, is unique because it uses a light activated drug therapy to destroy AKs. How does it work? Levulan Kerastick Topical Solution is applied to the AK. The solution is then absorbed by the AK cells where it is converted to a chemical that makes the cells extremely sensitive to light. When the AK cells are exposed to the BLU-U Blue Light Illuminator, a reaction occurs which destroys the AK cells.
The 2-part treatment offers the following conveniences:
- No prescription to fill
- No daily medication to remember
- Treatment is administered by a qualified healthcare professional
Levulan PDT can also fit your lifestyle:
- The 2-part, 2 office visit treatment is completed in less than 24 hours
- Low downtime*
- High ratings for cosmetic response1
- No scarring reported to date
*Patients treated with Levulan PDT should avoid exposure of the photosensitized lesions to sunlight or prolonged or intense light for at least 40 hours.
Up to 58 million Americans have actinic keratosis (AK). An AK has the potential to progress to squamous cell carcinoma (SCC), the second most common skin cancer. While most AKs remain benign, approximately 10 percent develop into SCC within an average of two years.1 Since there is no way to know ahead of time which ones will become cancerous. Frequent skin examinations are the key to early detection and prevention.